Identification and partial purification of a human natural killer cell proliferation-inducing factor by Saxena, Queen B. et al.
J. Biosci., Vol. 21, Number 4, June 1996, pp 455-469. © Printed in India. 
 
 
 
 
Identification and partial purification of a human natural killer 
cell proliferation-inducing factor 
 
QUEEN B SAXENA, RAJIV K SAXENA*†, RONALD H GOLDFARB, 
RONALD B HERBERMAN and THERESA L WHITESIDE 
Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 
15213, USA 
*School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India 
 
MS received 2 September 1995; revised 29 February 1996 
 
Abstract.  Culture supernatants of Concanavalin A activated human peripheral blood mono-
nuclear cells were found to contain a factor which induced proliferative response in normal 
peripheral blood mononuclear cells. This proliferation-inducing factor specifically induced and 
sustained proliferation of purified human NK cells but not of T or B cells. Although interleukin 
2 (IL12) also has proliferation-inducing effects on NK cells, the partially purified proliferation- 
inducing factor preparations contained no measurable IL2 contamination. Moreover, neu- 
tralizing anti-IL2 antibodies did not block the growth effect of proliferation-inducing factor on 
purified human NK cells. Other cytokines which were tested, including IL4, IL6, IL7, IL12, TNF 
and IFN, were all found to be inactive in the proliferation-inducing factor assay. While 
proliferation-inducing factor by itself had no effect on T-cell proliferation, IL2-induced prolifer- 
ation of T cells was significantly enhanced in the presence of proliferation-inducing factor, as was 
IL2-induced NK-cell proliferation. NK cells could be maintained in culture for at least a month in 
the presence of proliferation-inducing factor alone, but the cells lost their cytolytic activity after 
3-4 weeks in culture. Addition of IL2, to NK cells which had been cultured in the presence of 
proliferation-inducing factor, restored their cytotoxicity. Proliferation-inducing factor activity 
was partially purified on an anion exchange HPLC column. The molecular weight of prolifer- 
ation-inducing factor appeared to be about 10 kDa, based on its elution profile on a sizing HPLC 
column. Our results indicate that proliferation-inducing factor is a novel NK-cell proliferation- 
inducing factor. 
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1.  Introduction 
 
Clonal expansion of activated T cells is mediated by the release of IL2 by T-helper cells. 
While T cells need to be activated to express receptors for and to become sensitive to 
IL2, natural killer (NK) cells are immediately responsive to IL2, apparently due to their 
constitutive expression of intermediate affinity receptors for IL2 (Caligiuri et al 1990). 
In addition to IL2, a variety of other cell proliferation-stimulating lymphokines are 
known, which induce B-cell proliferation (Paul and Ohara 1987; Alderson et al 1987; 
Namen et al 1988) or proliferation of mast cells and granulocytes (Metcalf 1985; Ihle 
and Weinstein 1986). Such proliferation-inducing factors may play a crucial role in 
generating and sustaining the normal immune response. These factors may also be 
important as immuno-therapeutic agents and, when used singly or in combinations, for 
correcting defective immune functions. In addition, attempts are being made to use 
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lymphocytes or their subsets for adoptive immunotherapy in various human diseases 
and sufficient in vitro expansion of these cells depends on growth factors able to support 
their proliferation. IL2 has been extensively used for expansion of LAK cells or 
tumour-infiltrating lymphocytes (TIL5) in vitro (Rosenberg and Lotze 1986; Heo et al 
1987; Whiteside et al 1987; Wibke et al 1987). However, although IL2 is a growth factor 
for NK cells, it has been unable to support NK-cell growth for more than 15-21 days in 
culture (Rabinowich et al 1991). IL2, a recently discovered lymphokine (Kobayashi 
et al 1989; Stern et al 1990) appears to stimulate NK activity but does not support 
long-term culture of NK cells (Kobayashi et al 1989). 
In the present communication, we describe an additional cytokine which may have 
a role in regulating human NK and T cell proliferation. Evidence for this factor, named 
proliferation-inducing factor (P1F), was first obtained from our studies of a different 
factor, the MHC-I expression-augmenting factor or MHC-AF (Saxena et al 1992, 
1996). While studying MHC-AF, we found that partially-purified MHC-AF prepara- 
tions induced proliferation in normal human peripheral blood mononuclear cells 
(PBMC). This observation has suggested that either the MHC-AF preparations were 
contaminated with IL2, a known T-cell or T-cell growth factor, or that they 
contained a distinct growth-promoting cytokine. Since the MHC-AF preparations had 
no detectable IL2, we considered the possibility that a new PIF, different from IL2, was 
present in MHC-AF. Evidence is presented here for the presence of PIF, distinct from 
IL2 or other known cytokines, in the Con A supernatants of human PBMCs, and the 
characteristics of this factor are described. 
 
2. Materials and methods 
 
2.1 Reagents 
 
Various cytokines used in this study were obtained as gifts from the following sources: 
IL2 was kindly provided by Cetus Corp. (Emeryville, CA, USA); IL2, Hoffmann 
LaRoche (Nutley, NJ, USA); IL4 and IL7 by Sterling Drug Inc. (Malvern, PA, USA);
IL6 by Sandoz (Vienna, Austria); IFN-α by Roussel Uclaf (Romainville, France); and 
TNF- α by Knoll Pharmaceuticals (Whippany, NJ, USA). The hybridoma cell line, 
HB95 (secreting anti-MHC class I mAb), was obtained from American Type Culture 
Collection (ATCC; Bethesda, MD, USA). Neutralizing monoclonal antibodies to IL2 
were obtained from Genzyme (Cambridge, MA, USA). Reagents for gel filtration and 
isoelectric focusing were obtained from Sigma (St. Louis, MO, USA). 
 
2.2 Initial fractionation of PIF 
 
Preparations enriched in PIF activity were derived from culture supernatants of Con- 
A-activated peripheral blood derived mononuclear cells (PBMC). PBMC were isolated 
by Ficoll Hypaque density gradient centrifugation (Boyum 1974). Cells obtained by 
leukapheresis (Central Blood Bank of Pittsburgh) were diluted 20-fold in cold RPM1 
1640 medium (Gibco), and a 20 ml aliquot was layered on top of 10 ml of Lymphoprep 
solution (density 1·077 g/ml; Pharmacia) and centrifuged at 600g for 15 min. Mononuc- 
lear cells were harvested from the interface and washed three times with RPMI. PBMC 
(5 × 106 cells/ml) were cultured in RPMI 1640 medium supplemented with 5% fetal calf 
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serum (FCS; Gibco), glutamine (2 mM), penicillin (50U/ml), streptomycin (50 µg/ml)
and 25 mM HEPES (complete medium). Con-A was added to give a final concentration 
of 5 µg/ml and, after 3 days, culture supernatants were collected by centrifugation 
(2000 g for 15 min). Con-A supernatants were processed in batches of 1 to 4 liters. For 
each liter of a supernatant, 599 g of ammonium sulphate were added gradually at 4°C, 
and the supernatant allowed to remain overnight at 4°C. Precipitated proteins were 
pelleted by centrifugation at 10,000 g for 20 min and resuspended in 0.1 M glycine-HCl 
buffer at pH 2.0. The solution was dialyzed against the pH 2.0 buffer for 2 days, and 
then neutralized back to pH 7.0, using 10 N NaOH. Any insoluble material present at 
this stage was removed by centrifugation, and the solution concentrated to about 30 ml 
for each 1 liter of the starting material. The concentrate was fractionated on 
a 5 × 115 cm Sephadex G 100 column. For each Sephadex column separation, 30 ml of 
the concentrated supernatant were used. The column was run at 4°C, at a flow rate of 
1 ml/min, using phosphate-buffered saline (PBS). 
 
2.3 Preparative isoelectric focusing (IEF) 
 
The fractions with PIF activity separated on the Sephadex G 100 column were pooled, 
concentrated and dialyzed against 1% glycine. This pool was fractionated further by 
preparative IEF, as described elsewhere (Saxena 1987). The IEF fractions were dialyzed 
against PBS and assayed for PIF activity. Active fractions were pooled and concen- 
trated using a YM-5 Amicon ultrafiltration membrane. 
 
2.4  HPLC fractionation 
 
PIF preparations obtained after the Sephadex G 100 or IEF step, were further
fractionated on a HR8 (anion-exchange HPLC column, Waters) or a PP125 (sizing 
HPLC column, Waters) column. PIF preparation in 10 mM Tris-HCl buffer pH 8·2 
was applied on HR8 column and eluted using a gradient of 20 to 100% v/v of 0·5 M 
NaCl in 10mM Tris-HC1 buffer pH 8·2. Column fractions were filter-sterilized and
assayed for PIF activity. For PP125 column fractionation, 0·2 ml aliquots of PIF-
containing material in PBS were fractionated on a 10 ml column. 
 
2.5 Bioassay for PIF 
 
PBMC were adjusted to a concentration of 5 × 105 cells/ml and cultured (0·2 ml/well in 
96-well plates) with or without the test PIF preparations for 5 days. A pulse of [3H] 
thymidine (0·5 µCi/well, specific activity, 6·7 Ci/mrnol) was given during last 12 h of
culture and cells harvested for [3H] thymidine incorporation. In some experiments, 
purified NK or T cells were used in proliferation assays. 
 
2.6 MHC-AF bioassay 
 
Human tumour cells (HR, a gastric carcinoma cell line) were cultured at 0·1 × 106 
cells/ml in MEM complete medium, in the presence of the desired concentrations of the 
test fractions, for 2 to 3 days. At the end of culture, cells were harvested and stained for 
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class I MHC antigens as described before (Saxena et al 1988). Culture supernatant of 
HB95 hybridorna was used as a source of a mouse monoclonal antibody reactive to 
a non-polymorphic region of MHC class I antigens. Stained cells were fixed with 1% 
paraformaldehyde and analysed in a FACStar flowcytometer. 
 
2.7 Determinations of IL2 by ELISA or a bioassay 
 
ELISA for IL2 was performed using reagents from Collaborative Research, Bedford, 
MA, USA. The assay detects > 3IU/ml of 1L2 (WHO standard). An IL2 bioassay, 
using a CTLL line obtained from ATCC was performed as previously described (Gillis 
et al 1978). 
 
2.8  Isolation of T, B and NK cells 
 
PBMC preparations, isolated by Ficoll-Hypaque density-gradient centrifugation, were 
depleted of macrophages and B cells by passage through a nylon wool column, as 
described before (Saxena et al 1980). Cells were washed and adjusted to 4 × 106/ml and 
mixed with fetal calf serum and a 0·5% v/v suspension of sheep erythrocytes, in a 1:2:2 
ratio. Mixtures were centrifuged at 400 g for 5 min and incubated for 1 h at 29°C. The 
cell pellet was gently resuspended, and rosetted T-cells and non-rosetted cells were 
separated by Ficoll density gradient centrifugation. Erythrocytes in the rosette 
population were lysed by a brief hypotonic shock (water for 30 s), washed and T cells 
were purified further by panning, using flasks coated with anti-CD3 mAb (AIS, Menlo 
Park, CA, USA), as described before (Letessier et al 1991; Pricop et al 1991). Non- 
rosetted cells were treated with an anti-CD3 monoclonal antibody (1:50 diluted of an 
anti-CD3 from DAKO Corp., Carpinteria, CA, USA). Cells were washed and anti- 
body-coated cells (T cells) removed by using magnetic beads coated with a goat 
anti-mouse Ig antibody (30 beads/cell, 30 min at 4°C, Advance Magnetics; Cambridge, 
MA, USA). T cells bound to the beads were removed by using a powerful magnet. The 
process was repeated twice to ensure a complete removal of T cells. Residual cells (NK
cells) were washed and suspended in RPMI 1640 medium containing 10% v/v of 
human AB serum. In our experiments, this process enriched NK cells (identified by 
flowcytometric analysis as CD3– , CD16+ , CD56+ population) to levels ranging
from 92-95%, (Pricop et al 1991). 
For B cell isolation, the nylon wool step was replaced with a plastic adherence step to 
deplete macrophages. T cells were removed from this preparation by E-rosetting as 
described above. B cells were isolated by positive selection on plastic flasks pre-coated 
with anti-CD19 mAb (Wysocki and Sato 1978). 
 
 
3. Results 
 
3.1 Proliferation inducing activity in MHC-AF preparations 
 
We have recently described a novel factor in the culture supernatants of Con A- 
activated human PBMC which induces marked augmentation of the MHC class I 
antigen expression on a variety of tumour cell lines (Saxena et al 1992, 1996). This factor 
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named MHC-AF (MHC I expression-augmenting factor) was also found to induce 
proliferation in PBMC preparations. Figure 1 shows a dose-response curve of this 
effect. In this representative experiment, maximum incorporation was 10,000 cpm/well, 
which is significantly lower than a typical mitogen induced proliferative response 
(results not shown). To determine if proliferation-inducing activity could be separated 
from MHC-AF, fractions obtained by preparative IEF of the MHC-AF preparation 
recovered from a Sephadex G 100 column were tested for MHC augmenting as well as 
proliferation-inducing activity. Figure 2 shows the major peak of MHC-AF activity in 
fractions 9-11 (pI 5·7-6·2) and the same fractions also contained the proliferation-
inducing activity. Fractions 1 to 6 however had significant MHC-AF activity but no 
proliferation-inducing activity (henceforth called proliferation-inducing factor or PIF). 
 
 
3.2 Further separation of PIF and MHC-AF 
 
Preparations obtained by preparative IEF were further fractionated on HR8 anion 
exchange HPLC column (figure 3). PIF and MHC-AF elution profiles in figure 3A and 
Figure 1.  Proliferation of human PBMC in response to partially purified MHC-AF. Human
PBMC were cultured (5 × 105/ml, 0·2 ml/well) with various concentrations of a Sephadex 
G100 purified preparation of MHC-AF (Saxena et al 1995) for 5 days. 12 h prior to harvest, 
cells were pulsed with 0·5 µCi of [3H] thymidine/well. Each point in the graph represents 
a mean of three replicate assay wells. 
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Figure 2. Isoelectric focusing of PIF and MHC-AF activities. Preparation obtained after 
Sephadex G100 column fractionation (160 mg of protein) was fractionated by preparative 
isoelectric focusing as described before (Saxena 1987). Fractions were assayed for MHh-AF 
activity at 10% (v/v), using HR cells as indicator cells and for PIF activity at 5% (v/v), using 
purified human PBLs as described in § 2. 
 
 
B respectively, indicate that the two activities could be resolved as two different peaks 
on HR8 columns. Fractions positive for PIF activity did not have IL2 activity, as 
determined by CTLL assay. The IL2-containing peak eluted earlier than PIF (figure 3A) 
MHC-AF and PIF activities could also be resolved on HPLC sizing column (figure 4) 
The PP125 column was calibrated with protein markers of known molecular weight 
and using the calibration curve (not shown), the molecular weight of PIF was estimated 
to be 10 kDa, as compared to 35 kDa for MHC-AF. 
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Figure 3.  Fractionation of PIF, on an HR8 ion-exchange HPLC column. A pooled
Sephadex G-100 purified MHC-AF preparation was fractionated on HR8 ion-exchange 
column. The NaCI gradient used for elution was from 20% of 0.5 M NaCI in 0·01 M Tris-HCI 
buffer at pH 8·2 to 100% of 0·5 M NaCI in the same buffer. The fractions obtained were 
assessed for PIF ( ) and IL2 (O) (A) and MHC-AF (B) activities as described in §2. 
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Figure 4. Fractionation of PIF and MHC-AF activities on a PP125 HPLC column. 100 µl of 
a PIF preparation pooled after the IEF step were fractionated on a PP125 sizing HPLC 
column. Fractions of 250 µl were collected and assayed for PIF and MHC-AF activities at 
10% (v/v) by the procedure described in §2. The lower panel shows the protein profile, and the 
top panel shows the separate peaks with PIF (●) or MHC-AF (O) activities. 
 
 
3.3 Determination of cells responsive to PIF 
 
In order to determine the cell population (s) which proliferated in response to PIF, 
highly enriched populations of T cells, B cells and NK cells were obtained from PBMC 
and cultured in the presence of PIF-containing preparations. Figure 5 shows that 
human NK cells proliferated in response to PIF, while B and T cells did not. 
Proliferation of NK cells was dose-dependent on P1F with about 20-fold increase in 
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Figure 5.  Effect of PIF preparations on proliferation of T, B or NK cells. The purified cell
preparations were cultured (5 × 105 cells/ml, 02 ml/well) with various concentrations of PIF 
purified by IEF for 5 days. 5% V/V of PIF preparation corresponded to a final protein 
concentration of 10 µg/m1 in the assay medium. Cells were pulsed with [3H] thymidine for 12 h 
before harvest. Each point represents a mean of three replicate assay wells. Results of one 
representative experiment of the three done, have been shown. 
 
 
 
[3H] thymidine incorporation at the highest concentration tested, and was consistent- 
ly observed with HPLC column-purified as well as partially-purified PIF. These
observations indicated that PIF induced selective growth of human NK cells. 
 
 
3.4 Relationship of PIF to other known cytokines 
 
Since IL2 is known to induce proliferation of NK cells and IL12 is also known to have 
NK-cell stimulating effects (Kobayashi et al 1989; Stern et al 1990), we next compared 
the proliferative response of human purified NK cells to IL2, IL12 and PIF. Both IL2 
and PIF induced significant proliferative responses in NK cells (table 1). IL12 was, 
however, not active in our assay. In other similar experiments, recombinant IL12, did
occasionally induce a low level proliferative response in NK cells. However partially 
purified PIF preparations had no activity in IL12 bioassay (Maurice Gately, personal 
communication). 
In order to further clarify a possible relationship between PIF and IL2, we attempted 
to neutralize P1F activity by antibodies against human IL2. Results of a typical 
experiment, shown in table 2, indicate that monoclonal anti-human IL2 antibodies 
completely neutralized the proliferation-inducing abilities of IL2 but had no effect on 
PIF-induced NK-cell proliferation. Taken together, our results indicate that PIF and 
464 Queen B Saxena et al 
 
Table 1. Proliferative response of human NK cells to IL2, IL12 
and PIF. 
 
Purified human NK cells were cultured (5 × 105/ml, 0.2 ml/well) 
in the presence or absence of various concentrations of I L2, IL12 
or PIF (a post-IEF preparation) for five days. hells were pulsed 
with [3H] thymidine for 12 h prior to harvest. The data are mean 
cpm ± SD of Four replicate assay wells. 
 
 
 
Table 2. Effect of anti-IL2 Mab on the activity of PIF on NK 
cells. 
 
NK cells purified from PBMC were cultured (5 × 105/ml, 
0·2 ml/well) with IL2 (5 U/ml) or PIF purified by IEF (30 kig/m1) 
in the presence or absence of an anti-IL2 mAb capable of 
neutralizing 5 U/ml of IL2. After five days of culture, cells were 
pulsed with 0·5 µCi/ml of [3H] thymidine for 12 h before harvest. 
The PIF preparation used had no detectable IL2 levels. The data 
are mean cpm/well ± SD from one representative experiment of 
three performed. 
 
 
IL2 are distinct factors capable of inducing proliferation of human NK cells. A variety 
of other known cytokines, including IL4, IL6, IL7, IFN-α and TNF-α were also 
examined in proliferation assays with human NK cells and found to be unable to 
induce proliferation of these cells (results not shown). 
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3.5 Potentiation of IL2 activity by PIF 
 
Effects of a combination of PIF and IL2 on different subsets of human lymphocytes 
were also examined. When freshly isolated, purified T cell populations were used, IL2 
(up to a dose of 10 U/ml) had only a marginal proliferative effect (figure 6). PIF 
preparation by itself had no effect on T cell proliferation, but when added to the 
cultures together with IL2, a marked boosting of T cell proliferation was observed 
(figure 6). 
The effects of various combinations of IL2 and PIF on NK cell proliferation are 
shown in table 3. Human NK cells cultured in medium alone showed little [3H] 
thymidine incorporation, and addition of IL2 at 20-100 U/ml had a dose-dependent 
proliferation-inducing effect on these cells. Increasing the dose to 1,000 U/ml IL2 did 
not further augment proliferation of these cells. At all IL2 dose levels, addition of PIF 
resulted in an additive proliferative effect on NK cells. 
Induction of NK cell proliferation by PIF preparations was investigated further to 
determine if purified human NK cells could be cultured in the presence of PIF for 
prolonged time periods. We found that NK cells could be cultured for up to 1 month in 
the presence of PIF alone. Although NK cells proliferated in these cultures, they did not 
retain cytotoxic activity. Addition of IL2 to these proliferating yet non-cytolytic 
cultures resulted in up-regulation of cytolytic activity. Results in table 4 show that 
although NK cells cultured with PIF alone for 7 days had considerable cytotoxicity, by 
day 15, they were no longer cytotoxic. In all experiments, when IL2 was added as the 
second treatment to these cultures, the cytolytic activity of NK cells was restored. In 
 
 
Figure 6. Combined effects of IL2 and a PIF preparation on proliferation of T cells. Purified 
T cells were cultured (5 × 105/ml, 0·2 ml/well) with different concentrations of IL2 in the 
presence or absence of post-IEF PIF (1%, v/v). After 5 days of culture, cells were pulsed with 
[3H] thymidine (0·5 µCi/welI) for 12 h prior to harvest. Each point in the graph is a mean of 
three replicate assay wells. A representative experiment of three performed is shown. 
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Table 3. Effects of combination of PIF and IL2 on proliferation 
of human NK cells. 
 
NK cells purified from peripheral blood were cultured 
(5 × 105/ml, 0·2 ml/well) with various concentrations of human 
recombinant IL2 and an IEF-purified PIF preparation for 
5 days.Cells were harvested following a 12h pulse with [3H] 
thymidine (0·5 µCi/well). The data are mean cam ± SD obtained 
from four replicate assay welis. One representative experiment of 
six performed is shown. 
 
 
contrast, when NK cells were cultured in PIF alone, they had no cytolytic activity at the 
end of 15 or 25 day cultures, although they mediated NK activity on day 7 of culture 
(table 4). These results show that PIF can support long-term proliferation of NK cells 
in culture but not their cytotoxicity beyond day 7 of culture. 
 
 
4. Discussion 
 
In this manuscript, we have provided evidence for the presence of a factor in the culture 
supernatants of Con A-activated PBMC, which induces and supports proliferation of 
human purified NK cells. No prior activation of NK cells was required, and addition of 
PIF to resting NK cells allowed these cells to be cultured and expand for up to 25 days. 
During our purification of a different factor, named MHC class I expression- 
augmenting factor (MHC-AF), it became apparent that some of the fractions of the 
culture supernatants of Con-A-activated PBMC contained a proliferation-inducing 
factor which was distinct from MHC-AF. Although initial partially-purified MHC-AF 
preparations were found to induce proliferation of PBMC, further purification allowed 
us to separate MHC-AF and PIF. While PIF and MHC-AF activity peaks overlapped 
considerably on preparative IEFs, they could be resolved on either HR8 ion-exchange 
or PP125 sizing HPLC columns. The two factors not only had distinct biologic effects 
but were also different in their characteristics. For example, molecular weights of 
35 kDa and 10 kDa have been estimated for MHC-AF and PIF, respectively, based on 
the PP125 column elution profiles. These results clearly show that the MHC-AF and 
PIF activities reside in distinct molecules. 
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Table 4. Cytolytic activity of NK cells maintained in long-term culture with 
PIF and IL2. 
Purified human NK cells (5 × 105/m1) were cultured with PIF (10 µg/m1 of 
a post-IEF preparation) or IL2 (10 U/ml for culture durations up to 15 days, 
100 U/ml for culture durations more than 15 days) added at various times during 
culture, as indicated. At the end of the cultures, cells were harvested, washed and 
tested for cytotoxicity against K562 targets in 4 h 51Cr-release assays. 
 
 
Although PIF appears to be distinct from MHC-AF, its relationship to or identity 
with other known cytokines remained unclear. We, therefore, compared the effects of 
a variety of recombinant cytokines, including ILL IL2, IL4, IL6, IL7, IL12, IFNs and 
TNF with those of PIF. When isolated and purified subpopulations of lymphocytes 
were cultured in the presence of PIF, only preparations enriched in NK cells were able 
to proliferate in short- and long-term cultures. Besides IL2, none of the other cytokines 
tested were significantly active in inducing NK-cell proliferation. No IL2 could be 
detected in PIF preparations, either by a sensitive bioassay or by IL2-specific ELISA. 
Although these results do not rule out the presence of IL2 in levels below the detection 
limit of the assays utilized, PIF activity could not be neutralized by monoclonal 
antibodies to human IL2 which were able to neutralize 5 U of IL2 in parallel 
experiments. The combination of PIF and IL2 also resulted in improved proliferative 
responses of purified NK and T cell preparations, to IL2 as compared to those in the 
presence of IL2 alone. 
IL12, a disulphide linked heterodirner of 75 kDa is an NK-cell stimulatory lym- 
phokine that has been described and cloned (Kobayashi et al 1989; Stern et al 1990). In 
some of our experiments, IL12 induced a weak proliferative response in purified NK 
cells. However, this effect was not consistently seen and when observed was much lower 
than the effect of PIF. Moreover, the molecular weight of PIF, estimated at 10 kDa in 
preliminary experiments, is not comparable with that of IL12 (75 kDa). Another 
cytokine IL15 has recently been described, which like IL2, induces proliferation in 
CTLL cell line (Grabstein et al 1994). PIF is unlikely to be IL15 since the former has no 
effect on the proliferative activity of CTLL cell line (figure 3). 
468 Queen B Saxena et al 
 
Taken together, our results indicate that a novel proliferation-inducing factor is 
present in supernatants of Con A-activated PBMC. This factor, PIF when used alone, 
has activity restricted to NK cells, but when used in combination with IL2, it also 
promotes T cell proliferation. Further purification and characterization of PIF is 
necessary to gain a better understanding of its nature. An NK cell proliferating factor is 
of great potential interest, since it has been very difficult to grow human NK cells in 
long-term cultures, even in the presence of feeder cells and mixtures of various 
cytokines (Rabinowich et al 1991). With the availability of PIF, it may be possible to 
expand human NK cells in Vitro and to obtain numbers of NK cells necessary for 
immunotherapy in clinical trials (Hercend et al 1990; Whiteside et al 1990). Studies are 
in progress in our laboratory to isolate PIF and to demonstrate its applicability for 
large-scale culture of human NK cells. 
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